<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04446962</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2019-02</org_study_id>
    <secondary_id>2019-003632-23</secondary_id>
    <nct_id>NCT04446962</nct_id>
  </id_info>
  <brief_title>LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)</brief_title>
  <acronym>LOC-R01</acronym>
  <official_title>LOC-R01: Randomized Phase Ib/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) as a Targeted Induction Treatment for Patients Aged 18 to 60 With a Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to improve the first-line induction chemotherapy, by combining either
      Ibrutinib, or Lenalidomide, to a conventional immuno- chemotherapy of R-MPV type
      (Rituximab-Methotrexate-Procarbazine-Vincristine). This is a randomized Phase II trial,
      preceded by a dose escalation phase Ib. The objective of the phase Ib is to rule out any
      limiting toxicity of the new treatment associations, and to determine the recommended dose of
      Lenalidomide and Ibrutinib to be used in the phase II. In the phase II study, patients will
      receive 4 cycles of R-MPV + Lenalidomide or 4 cycles of R-MPV + Ibrutinib. The therapeutic
      response will be evaluated after the 2nd and the 4th cycle. Patients in good therapeutic
      response will proceed to the consolidation phase with Autologous Stem Cell Transplantation
      (ASCT).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this proposal is to test the feasibility and efficacy of two targeted
      induction chemotherapies obtained by adding either Lenalidomide or Ibrutinib to a standard
      Rituximab-High Dose (HD) Methotrexate (MTX) based induction chemotherapy regimen. The R-MPV
      regimen is chosen as the backbone chemotherapy because of its wide use with robust
      reproducible results and a good and manageable toxicity profile
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2020</start_date>
  <completion_date type="Anticipated">January 15, 2031</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT) during the first cycle of treatment for each treatment arm.</measure>
    <time_frame>1 month</time_frame>
    <description>Occurrence of a Dose Limiting Toxicity (DLT) during the first cycle of treatment for each treatment arm. The phase Ib is a 3+3 dose escalation design</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Response (CR) rate including unconfirmed Complete Response (uCR) at the end of the 4 cycles of induction therapy</measure>
    <time_frame>4 months</time_frame>
    <description>The primary endpoint for the phase II part of the study is the Complete Response (CR) rate including unconfirmed CR (CR+uCR) at the end of the 4 cycles of induction therapy. Assessment of response will be based on the International Primary Central Nervous System Lymphoma Collaborative Group (IPCG)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rates (CR + uCR) after 2 cycles of induction treatment</measure>
    <time_frame>2 months</time_frame>
    <description>Assessment of response will be based on the International Primary Central Nervous System Lymphoma Collaborative Group (IPCG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response (CR + uCR + Partial Response(PR)), stable disease (SD), and primary refractory patients (PD) after 2 cycles of induction treatment</measure>
    <time_frame>2 months</time_frame>
    <description>Assessment of response will be based on the International Primary Central Nervous System Lymphoma Collaborative Group (IPCG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response (CR + uCR + Partial Response(PR)), stable disease (SD), and primary refractory patients (PD) after 4 cycles of induction treatment</measure>
    <time_frame>4 months</time_frame>
    <description>Assessment of response will be based on the International Primary Central Nervous System Lymphoma Collaborative Group (IPCG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>142 months</time_frame>
    <description>Overall Survival (OS) will be calculated from the date of randomization to the date of death, whatever the cause. Patients alive at the date of last contact will be censored at this date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>142 months</time_frame>
    <description>Progression-Free Survival (PFS) will be calculated from the date of randomization to the date of progression or death (if the patient does not progress). Patients alive without progression at the date of last contact will be censored at this date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The severity of the toxicity of treatment induction or ASCT</measure>
    <time_frame>7 months</time_frame>
    <description>Toxicity of treatment induction or ASCT will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE 5.0) whenever possible and described by system organ class, preferred term</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients who will receive ASCT</measure>
    <time_frame>7 months</time_frame>
    <description>The percentage of patients who will receive ASCT will be presented</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <condition>Central Nervous System Neoplasms, Primary</condition>
  <arm_group>
    <arm_group_label>Arm A: R-MPV with Lenalidomide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lenalidomide in association with R-MPV as a targeted induction treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: R-MPV with Ibrutinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibrutinib in association with R-MPV as a targeted induction treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Patients will receive 4 cycles of induction chemotherapy with R-MPV + Lenalidomide using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.</description>
    <arm_group_label>Arm A: R-MPV with Lenalidomide</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Patients will receive 4 cycles of induction chemotherapy with R-MPV + Ibrutinib, using the Maximum Tolerated Dose (MTD) of Lenalidomide and Ibrutinib as determined in the phase-Ib part of the study.</description>
    <arm_group_label>Arm B: R-MPV with Ibrutinib</arm_group_label>
    <other_name>Imbruvica</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Newly diagnosed Primary Central Nervous System Lymphoma (PCNSL).

          2. Aged between 18 and 60 (≥18 and ≤ 60).

          3. Histological confirmed diagnosis of Primary central nervous system lymphoma of Diffuse
             Large B-Cell Lymphomas (DLBCL) type OR patients with a measurable typical cerebral
             lesion on MRI with a diagnosis made by cytology and/or by flow cytometry on the
             vitreous or on the cerebral spinal fluid.

          4. Measurable lesion on MRI with gadolinium enhancement.

          5. Adequate hematological, renal and hepatic function (Laboratory Parameters realized
             within 14 days before inclusion):

               1. Absolute neutrophil count (ANC) ≥ 1000/mm3

               2. Platelets ≥ 100,000/mm3 independent of transfusion support

               3. Alanine aminotransferase and aspartate aminotransferase ≤ 3 x Upper Limit of
                  Normal (ULN)

               4. Total bilirubin ≤ 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or
                  of non-hepatic origin

               5. Estimated Glomerular Filtration Rate ≥ 60 mL/min/1.73m2.

          6. Able to swallow capsules.

          7. Karnofsky Performance Status (KPS): 40-100% for the phase Ib and no restriction on the
             KPS for the phase II.

          8. Able to understand teratogenic risks of the Lenalidomide and Ibrutinib. Patient must
             be able to understand and fulfill the Lenalidomide Pregnancy Prevention Plan
             requirements. This plan may be accepted by the person of confidence in case of
             impaired cognitive status of the patient.

          9. Women of childbearing potential (WCBP) and men who are sexually active must be
             practicing a highly effective method of birth control. Women should avoid a pregnancy
             while taking treatment by Lenalidomide or Ibrutinib and for up to 1 month after ending
             treatment. Men must agree to not to father a child or donate sperm during treatment by
             Lenalidomide or Ibrutinib and up to 3 months after the last dose of study drug.

         10. Women of childbearing potential (WCBP)* must have a negative serum (Bêta-human
             Chorionic Gonadotropin (Bêta-hCG)) or urine pregnancy test at inclusion.

         11. Signed informed consent, which could be signed by a person on confidence in case the
             neurologic status of the patient does not allow him to understand and/or to sign.

        Exclusion Criteria:

          1. Histology other than DLBCL.

          2. Positive HIV serology.

          3. Active viral infection with Hepatitis B or C virus.

          4. Preexisting immunodeficiency and/or organ transplant recipient.

          5. Isolated Central Nervous System (CNS) relapse of systemic Non-Hodgkin's Lymphoma.

          6. Prior treatment for PCNSL (except corticosteroids).

          7. Isolated primary vitreo-retinal lymphoma.

          8. Major surgery, within 4 weeks prior to the first dose of study drug. Stereotactic
             biopsy and vitrectomy are not considered major surgery.

          9. History of stroke or intracranial hemorrhage (except minor post biopsy hemorrhage)
             within 6 months prior to inclusion.

         10. Requires anticoagulation with warfarin or equivalent vitamin K antagonists.

         11. Requires treatment with strong CYP3A4 inhibitors.

         12. Pregnancy or lactation.

         13. Clinically significant cardiovascular disease.

         14. Any other active malignancy, except basocellular carcinoma and non-invasive cervix
             cancer.

         15. Inclusion in another experimental anti-cancer drug therapy.

         16. No social security affiliation.

         17. Persons under legal protection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Fumoleau, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carole SOUSSAIN, MD</last_name>
    <phone>+33 1 47 11 15 15</phone>
    <email>carole.soussain@curie.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle Turbiez</last_name>
    <phone>+33 1 56 24 56 30</phone>
    <email>drci.promotion@curie.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Magalie JORIS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Magalie JORIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie-Pierre MOLES-MOREAU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marie-Pierre MOLES-MOREAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Adrien CHAUCHET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Adrien CHAUCHET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anna SCHMITT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anna SCHMITT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gandhi DAMAJ, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gandhi DAMAJ, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Cécile MOLUCON-CHABROT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cécile MOLUCON-CHABROT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Colmar</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Guido AHLE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guido AHLE Guido AHLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Créteil</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Louise ROULIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Louise ROULIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier CASASNOVAS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier CASASNOVAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Rémy Rémy GRESSIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rémy GRESSIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Franck MORSCHHAUSER, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Franck MORSCHHAUSER, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Julie ABRAHAM, MD</last_name>
    </contact>
    <investigator>
      <last_name>ABRAHAM Julie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Hervé GHESQUIERES, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hervé GHESQUIERES, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La Timone Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier CHINOT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier CHINOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Luc TAILLANDIER, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Luc TAILLANDIER, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Thomas GASTINNE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thomas GASTINNE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Frédéric PEYRADE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frédéric PEYRADE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Carole Soussain, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carole Soussain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75006</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lise WILLEMS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lise WILLEMS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Caroline HOUILLIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Caroline HOUILLIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Vincent DELWAIL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vincent DELWAIL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Thierry LAMY De La CHAPELLE, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Thierry Thierry LAMY De La CHAPELLE, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabrice JARDIN, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Fabrice JARDIN, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUCT -Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lucie Obéric, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lucie Obéric, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Emmanuel GYAN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Emmanuel GYAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 22, 2020</study_first_submitted>
  <study_first_submitted_qc>June 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2020</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Nervous System</keyword>
  <keyword>Primary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

